Clinical trials: End-Stage Heart Failure
Heart Failure, Ventricular Assist Device
Influence of Telemonitoring on the Management of LVAD-patients
The current study aims to investigate whether telemedical monitoring in patients with terminal heart failure and an implanted left ventricular assist device (LVAD) has an influence on LVAD-associated complications…
- Conditions
- Heart Failure, Ventricular Assist Device, Telemedicine
- Trial name
- NCT04613401
- Testing
- questionnaire (observational study)
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- University Hospital, Essen
Heart Failure
A Study of Ponsegromab in People With Heart Failure
The primary purpose of this clinical trial is to compare the effects of study medicine (Ponsegromab/PF-06946860) with a placebo (an injection that looks like the study medicine but does not contain the active medicine) to find…
- Trial name
- GARDEN TIMI 74 (NCT05492500)
- Testing
- Main cohort (Cohort A): Ponsegromab low dose, Main cohort (Cohort A): Ponsegromab medium dose, Main cohort (Cohort A): ponsegromab high dose
- Where
- 122 sites in United States, Australia and 9 more
- Volunteers
- 455 people
- Sponsor
- Pfizer
Respiratory Failure, Shock
Comparing Post Cardiac Surgery Outcomes in ESRD Patient's With Early Dialysis Versus Standard Care
End-stage renal disease (ESRD) is an important risk factor for coronary and valvular cardiac disease leading to cardiac surgery.
- Conditions
- Respiratory Failure, Shock, Coagulopathy
- Trial name
- NCT04705701
- Testing
- Hemodialysis
- Sponsor
- Northwell Health
Dyspnea, Heart Failure
Dyspnea and Biomarkers in a Prehospital Setting
In patients presenting with acute dyspnea in a pre-hospital setting, the early and correct diagnosis may present a significant clinical challenge.
- Conditions
- Dyspnea, Heart Failure, Asthma, COPD
- Trial name
- NCT00878475
- Where
- Slovenia
- Volunteers
- 546 people
- Sponsor
- Community Healthcare Center dr. Adolf Drolc Maribor (HCM)
End Stage Renal Disease, Chronic Kidney Disease
Risk Stratification in End Stage Renal Disease (ESRD) - ISAR Study
The purpose of this study is to evaluate the use of non-invasive markers of the autonomic function and micro- and macrocirculation to predict mortality and cardiovascular end points in end-stage renal disease patients.
- Conditions
- End Stage Renal Disease, Chronic Kidney Disease, Cardiovascular Event, Sudden Cardiac Death
- Trial name
- ISAR (NCT01152892)
- Where
- 17 sites in Germany
- Volunteers
- 500 people
- Sponsor
- Technical University of Munich
Heart Failure, Congenital
Etablishment of Follow-up System and End-Stage Heart Registration Platform for Pediatric Heart Failure
Establish a follow-up management system for pediatric heart failure and a registration platform for end-stage heart failure
- Conditions
- Heart Failure, Congenital, End-stage Heart Failure
- Trial name
- NCT06345521
- Testing
- No intervention
- Where
- China
- Volunteers
- 100 people
- Sponsor
- China National Center for Cardiovascular Diseases
End-Stage Heart Failure, Bridge-to-Transplant LVAD Placement (BTT)
Development & Testing of a Decision Aid for LVAD Placement
The goal of this project is to develop a patient-centered decision aid for decision-making about end-stage heart failure treatment.
- Conditions
- End-Stage Heart Failure, Bridge-to-Transplant LVAD Placement (BTT), Destination Therapy LVAD Placement (DT), Refusal of LVAD Placement (Decliners)
- Trial name
- VADDA (NCT02248974)
- Testing
- LVAD Decision Aid
- Where
- 7 sites in United States
- Volunteers
- 98 people
- Sponsor
- Baylor College of Medicine
Atrial Fibrillation, End-stage Kidney Disease
Compare Apixaban and Vitamin-K Antagonists in Patients With Atrial Fibrillation (AF) and End-Stage Kidney Disease (ESKD)
The Study is an open-labeled, randomized controlled trial, phase IIIb. Its objective is to assess the safety of the factor Xa inhibitor apixaban versus the vitamin-K antagonist (VKA) phenprocoumon in patients with NVAF and ESKD…
- Trial name
- AXADIA (NCT02933697)
- Testing
- Apixaban, Phenprocoumon
- Where
- Germany
- Volunteers
- 108 people
- Sponsor
- Atrial Fibrillation Network
Heart Failure NYHA Class III, Heart Failure NYHA Class IV
Family Palliative and End-of-Life Care for Advanced Heart Failure
Overall objective is to test whether the 5-weekly family home palliative and end-of-life care (FamPALcare) intervention educational and supportive sessions will improve rural home end-of-life and palliative care (EOLPC) for…
- Trial name
- NCT04153890
- Testing
- FamPALcare
- Where
- United States
- Volunteers
- 78 people
- Sponsor
- West Virginia University
Dilated Cardiomyopathy
Safety and Efficacy Study of Stem Cell Transplantation to Treat Dilated Cardiomyopathy
Several studies have documented that transplantation of bone marrow-derived cells (BMC) following acute myocardial infarction is associated with a reduction in infarct scar size and improvements in left ventricular function and…
- Trial name
- NCT00629018
- Testing
- CD34+ autologous stem cell transplantation, Bone Marrow Stimulation, SC therapy
- Where
- Slovenia
- Volunteers
- 110 people
- Sponsor
- University Medical Centre Ljubljana
Cardiovascular Diseases, Coronary Artery Disease
ISCHEMIA-Chronic Kidney Disease Trial
The purpose of the ISCHEMIA-CKD trial is to determine the best management strategy for patients with stable ischemic heart disease (SIHD), at least moderate inducible ischemia and advanced chronic kidney disease (CKD; estimated…
- Conditions
- Cardiovascular Diseases, Coronary Artery Disease, Heart Diseases, Myocardial Ischemia
- Trial name
- ISCHEMIA-CKD (NCT01985360)
- Testing
- Cardiac Catheterization, Coronary Artery Bypass Graft Surgery, Percutaneous Coronary Intervention
- Where
- United States
- Volunteers
- 777 people
- Sponsor
- NYU Langone Health
End-stage Heart Failure, Left Ventricular Assist Device
LVAD Index and Clinical Outcomes in Continuous-Flow LVAD Patients
This single-center, observational study evaluated the LVAD index, defined as device-estimated pump flow divided by body surface area, in adult patients supported with continuous-flow left ventricular assist devices.
- Conditions
- End-stage Heart Failure, Left Ventricular Assist Device, Mechanical Circulatory Support
- Trial name
- LVAD-INDEX (NCT07633535)
- Testing
- HeartWare Ventricular Assist Device, HeartMate 3 Left Ventricular Assist Device
- Where
- Turkey (Türkiye)
- Volunteers
- 34 people
- Sponsor
- Gaziantep City Hospital
Pleural Effusion, Heart Failure
Comparing the Diagnostic Sensitivity and Specificity of Pleural Fluid N-Terminal Pro B-type Natriuretic Peptide (NT-proBNP) and Other Biochemical Gradient Criteria in Distinguishing Heart Failure and Non-heart Failure Related Pleural Effusions (CENTRE Study)
To assess the discriminative properties of pleural fluid (PF) N-terminal-proB-type-natriuretic-peptide (NTproBNP) levels in identifying heart failure (HF)-associated pleural effusions (PE).
- Conditions
- Pleural Effusion, Heart Failure, Malignant Neoplasm, Fluid Overload
- Trial name
- NCT05797649
- Where
- Hong Kong
- Volunteers
- 160 people
- Sponsor
- Chinese University of Hong Kong
End Stage Heart Disease, Heart Failure
Transitional Palliative Care in End-stage Heart Failure
Palliative care for end-stage organ failure patients has been included as one of the key programs to be implemented in 2011-2012 in the Hospital Authority, Hong Kong.
- Trial name
- NCT02086305
- Testing
- Transitional Care Model, Usual care
- Where
- 3 sites in Hong Kong
- Volunteers
- 84 people
- Sponsor
- The Hong Kong Polytechnic University
End Stage Renal Disease, Cardiac Insufficiency
Invasive Monitoring of Pulmonary Artery Pressure (PAP) Among Dialysis Treated Patients
The purpose of this study is examine whether invasive pulmonary artery pressure (PAP) monitoring could be beneficial for the patients in dialysis treatment.
- Trial name
- NCT02862197
- Where
- Finland
- Volunteers
- 8 people
- Sponsor
- Joint Authority for Päijät-Häme Social and Health Care
Kidney Diseases, End-Stage Kidney Disease
Major Outcomes With Personalized Dialysate TEMPerature
People with failed kidneys need an artificial kidney machine (called dialysis) to remove toxins and extra fluid from the body. Most patients receive dialysis treatments at a hospital three times a week.
- Conditions
- Kidney Diseases, End-Stage Kidney Disease, Hemodialysis
- Trial name
- MyTEMP (NCT02628366)
- Testing
- Personalized Dialysate Temperature
- Where
- Canada
- Volunteers
- 84 people
- Sponsor
- London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's
Chronic or Acute Advanced Heart Failure
South Of France Cardiac Assist Registry
Chronic heart failure is a common disease. It is also a serious disease with a mortality of 50% at 5 years, representing a significant cost in terms of public health expenditure.
- Trial name
- SOFCAR (NCT02877446)
- Where
- France
- Volunteers
- 200 people
- Sponsor
- University Hospital, Montpellier
End Stage Heart Failure
Sildenafil for the Prevention of Right Heart Failure Following LVAD Implantation
Continuous-flow left ventricular assist devices (LVAD) move blood from the left ventricle (the largest chamber of the heart) to the aorta (the body's main artery) to help the heart better meet the needs of the body and to improve…
- Trial name
- NCT03356353
- Testing
- Sildenafil Citrate
- Where
- 4 sites in Canada
- Volunteers
- 24 people
- Sponsor
- University of Calgary
End Stage Renal Disease, Congestive Heart Failure
Spironolactone Safety in Dialysis Patients
Cardiovascular disease is the leading cause of death and disproportionately prevalent in patients with kidney disease. Spironolactone has been shown to improve survival in the general population with heart failure by up to 30%.
- Trial name
- NCT00328809
- Testing
- spironolactone
- Where
- United States
- Sponsor
- State University of New York - Upstate Medical University
Heart Failure
Interval Versus Continuous Training in LVAD Patients
Patients with a left ventricular assist device (LVAD) will be randomized to either a moderate continuous (MCT, 50-60% of VO2peak) or interval training (IT, 80-90% of VO2peak) group for 6 weeks with 3 sessions per week, lasting…
- Trial name
- TrainLVAD (NCT05121077)
- Testing
- Training
- Where
- Germany
- Volunteers
- 10 people
- Sponsor
- University Hospital, Essen